Submission of the manuscript is online via e-mail or

Tel: +7 903 250 5288

Editorial Correspondence e-mail

Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail

Tel: +7 917 561 9505

SCImago Journal & Country Rank

    1. Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russian Federation (Sechenovskiy University) (119991, Moscow, Russia)

    Abstract: The remaining disorders of stool, supposedly of a functional nature, similar to the symptoms of irritable bowel syndrome (IBS), in patients with inflammatory bowel disease (IBD) in remission during the last 16 years are actively discussed in the literature. A great similarity in the clinical manifestations and mechanisms of the formation of true IBS and IBD-IBS was revealed. As the combining factors of these two pathological conditions, occult inflammation in the intestinal wall, intestinal motility disorders, visceral hypersensitivity, intestinal microbiome disorder and increased permeability of the mucosa are considered. The role of psychological stress in the formation of the IBD-IBS remains underestimated and insufficiently investigated. In patients with true IBS and IBD-IBS, the indices of depression, actual and personal anxiety, alexithymia are statistically significantly higher than in healthy individuals and do not differ among themselves. An additional confirmation of similar changes in the psychovegetative status in patients with IBS and IBD-IBS is the study of one of the relatively new psychometric indicators, the Visceral Sensitivity Index (VSI), which characterizes specific anxiety with respect to gastroenterological symptoms of the disease. Аn integrative index of all psycho-vegetative changes in patients is an indicator of the quality of life. As in patients with true IBS, and with IBD-IBS, according to the literature, Noah decrease in both physical and mental qOL component. The article deals with modern information about similarities and differences mechanisms of IBS and IBD in remission with IBS-like symptoms, which indicate large differential diagnostic difficulties in distinguishing these disorders.

      1. Isgar B, Harman M, Kaye MD, Whorwell PJ. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut. 1983 Mar;24(3):190–192.
      2. Simrén M1, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Björnsson ES.Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol. 2002 Feb;97(2):389–96.
      3. Teruel C, Garrido E, Mesonero F.Diagnosis and management of functional symptoms in inflammatory bowel disease in remission. World J Gastrointest Pharmacol Ther. 2016 Feb 6;7(1):78–90.
      4. Bercik P1, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol Clin North Am. 2005 Jun; 34(2):235–45, vi–vii.
      5. Grover M, Herfarth H, Drossman DA. The functionalorganic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome. Clin Gastroenterol Hepatol. 2009 Jan;7(1):48–53.
      6. Long MD, Drossman DA.Inflammatory bowel disease, irritable bowel syndrome, or what?: A challenge to the functional-organic dichotomy. Am J Gastroenterol. 2010 Aug;105(8):1796–8.
      7. Zaman MS, Robson KM, Lembo AJ. Overlap of irritable bowel syndrome (IBS) symptoms in patients with inflammatory bowel disease (IBD) Am J Gastroenterol. 2002;97 Suppl:S284.
      8. Minderhoud IM, Oldenburg B, Wismeijer JA, van Berge Henegouwen GP, Smout AJ. IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig Dis Sci. 2004;49:469–474.
      9. Farrokhyar F, Marshall JK, Easterbrook B, Irvine EJ. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis. 2006;12:38–46.
      10. Ansari R, Attari F, Razjouyan H, Etemadi A, Amjadi H, Merat S, Malekzadeh R. Ulcerative colitis and irritable bowel syndrome: relationships with quality of life. Eur J Gastroenterol Hepatol. 2008;20:46–50.
      11. Keohane J, O’Mahony C, O’Mahony L, O’Mahony S, Quigley EM, Shanahan F. Irritable bowel syndrometype symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol. 2010;105:1788, 1789–1794; quiz 1795
      12. Piche T, Ducrotté P, Sabate JM, Coffin B, Zerbib F, Dapoigny M, Hua M, Marine-Barjoan E, Dainese R, Hébuterne X. Impact of functional bowel symptoms on quality of life and fatigue in quiescent Crohn disease and irritable bowel syndrome. Neurogastroenterol Motil. 2010;22:626–e174.
      13. Barratt SM, Leeds JS, Robinson K, Shah PJ, Lobo AJ, McAlindon ME, Sanders DS. Reflux and irritable bowel syndrome are negative predictors of quality of life in coeliac disease and inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011;23:159–165.
      14. Bryant RV, van Langenberg DR, Holtmann GJ, Andrews JM. Functional gastrointestinal disorders in inflammatory bowel disease: impact on quality of life and psychological status. J Gastroenterol Hepatol. 2011;26:916–923.
      15. Jelsness-Jørgensen LP, Bernklev T, Moum B. Fatigue and disease-related worries among inflammatory bowel disease patients in remission; is it a reflection of coexisting IBS-like symptoms? A short report. J Psychosom Res. 2012;73:469–472.
      16. Kim ES, Cho KB, Park KS, Jang BI, Kim KO, Jeon SW, Jung MK, Kim EY, Yang CH. Predictive factors of impaired quality of life in Korean patients with inactive inflammatory bowel disease: association with functional gastrointestinal disorders and mood disorders. J Clin Gastroenterol. 2013;47:e38–e44.
      17. Berrill JW, Green JT, Hood K, Campbell AK. Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity. Aliment Pharmacol Ther. 2013;38:44–51.
      18. Jonefjäll B, Strid H, Ohman L, Svedlund J, Bergstedt A, Simren M. Characterization of IBS-like symptoms in patients with ulcerative colitis in clinical remission. Neurogastroenterol Motil. 2013;25:756–e578.
      19. Vivinus-Nébot M, Frin-Mathy G, Bzioueche H, Dainese R, Bernard G, Anty R, Filippi J, Saint-Paul MC, Tulic MK, Verhasselt V, et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut. 2014;63:744–752.
      20. Fukuba N, Ishihara S, Tada Y, Oshima N, Moriyama I, Yuki T, Kawashima K, Kushiyama Y, Fujishiro H, Kinoshita Y. Prevalence of irritable bowel syndromelike symptoms in ulcerative colitis patients with clinical and endoscopic evidence of remission: prospective multicenter study. Scand J Gastroenterol. 2014;49:674–680.
      21. Toshihiko Tomita,1 Yu Kato,1 Mayu Takimoto,1 Takahisa Yamasaki,1 Takashi Kondo,1 Tomoaki Kono,1 Katsuyuki Tozawa,1 Yoko Yokoyama,2 Hisatomo Ikehara,1 Yoshio Ohda,1 Tadayuki Oshima,1 Hirokazu Fukui,1 Shigemi Tanaka,3 Masayuki Shima,4 Jiro Watari,1 and Hiroto Miwa1,* Prevalence of Irritable Bowel Syndrome– like Symptoms in Japanese Patients with Inactive Inflammatory Bowel DiseaseJ Neurogastroenterol Motil. 2016 Oct; 22(4): 661–669.
      22. Keszthelyi D, Jonkers DM, Hamer HM, Masclee AA. Letter: the role of sub-clinical inflammation and TRPV1 in the development of IBS-like symptoms in ulcerative colitis in remission. Aliment Pharmacol Ther. 2013;38:560–561.
      23. Annese V, Bassotti G, Napolitano G, Usai P, Andriulli A, Vantrappen G. Gastrointestinal motility disorders in patients with inactive Crohn’s disease. Scand J Gastroenterol. 1997;32:1107–1117;
      24. Bassotti G, de Roberto G, Chistolini F, Sietchiping-Nzepa F, Morelli O, Morelli A. Twenty-four-hour manometric study of colonic propulsive activity in patients with diarrhea due to inflammatory (ulcerative colitis) and non-inflammatory (irritable bowel syndrome) conditions. Int J Colorectal Dis. 2004;19:493–497.
      25. Bassotti G, Villanacci V, Mazzocchi A, Castellani D, Giuliano V, Corsi S, Morelli A. Colonic propulsive and postprandial motor activity in patients with ulcerative colitis in remission. Eur J Gastroenterol Hepatol. 2006;18:507–510.
      26. Minderhoud IM, Smout AJ, Oldenburg B, Samsom M. A pilot study on chemospecific duodenal visceral sensitivity in inflammatory bowel disease in remission. Digestion. 2006;73:151–159.
      27. Lindgren S, Stewenius J, Sjölund K, Lilja B, Sundkvist G. Autonomic vagal nerve dysfunction in patients with ulcerative colitis. Scand J Gastroenterol. 1993;28:638– 642.
      28. Coruzzi P, Castiglioni P, Parati G, Brambilla V, Brambilla L, Gualerzi M, Cademartiri F, Franzè A, De Angelis G, Di Rienzo M, et al. Autonomic cardiovascular regulation in quiescent ulcerative colitis and Crohn’s disease. Eur J Clin Invest. 2007;37:964–970.
      29. Sharma P, Makharia GK, Ahuja V, Dwivedi SN, Deepak KK. Autonomic dysfunctions in patients with inflammatory bowel disease in clinical remission. Dig Dis Sci. 2009;54:853–861.
      30. Ananthakrishnan AN, Issa M, Barboi A, Jaradeh S, Zadvornova Y, Skaros S, Johnson K, Otterson MF, Binion DG. Impact of autonomic dysfunction on inflammatory bowel disease. J Clin Gastroenterol. 2010;44:272–279
      31. Bernstein CN, Niazi N, Robert M, Mertz H, Kodner A, Munakata J, Naliboff B, Mayer EA. Rectal afferent function in patients with inflammatory and functional intestinal disorders. Pain. 1996;66:151–161.
      32. Chang L, Munakata J, Mayer EA, Schmulson MJ, Johnson TD, Bernstein CN, Saba L, Naliboff B, Anton PA, Matin K. Perceptual responses in patients with inflammatory and functional bowel disease. Gut. 2000;47:497–505.
      33. Akbar A, Yiangou Y, Facer P, Brydon WG, Walters JR, Anand P, Ghosh S. Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. Gut. 2010;59:767–774.
      34. Keszthelyi D, Troost FJ, Jonkers DM, Helyes Z, Hamer HM, Ludidi S, Vanhoutvin S, Venema K, Dekker J, Szolcsányi J, et al. Alterations in mucosal neuropeptides in patients with irritable bowel syndrome and ulcerative colitis in remission: a role in pain symptom generation? Eur J Pain. 2013;17:1299–1306.
      35. Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut. 2008;57:923–929.
      36. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126:693–702.
      37. van Hoboken EA, Thijssen AY, Verhaaren R, van der Veek PP, Prins FA, Verspaget HW, Masclee AA. Symptoms in patients with ulcerative colitis in remission are associated with visceral hypersensitivity and mast cell activity. Scand J Gastroenterol. 2011;46:981–987.
      38. Minderhoud IM, Oldenburg B, Schipper ME, ter Linde JJ, Samsom M. Serotonin synthesis and uptake in symptomatic patients with Crohn’s disease in remission. Clin Gastroenterol Hepatol. 2007;5:714–720.
      39. Gwee KA. Post-Infectious Irritable Bowel Syndrome, an Inflammation-Immunological Model with Relevance for Other IBS and Functional Dyspepsia. J Neurogastroenterol Motil. 2010;16:30–34.
      40. Pogromov A.P., Mnatsakanyan M.G., Tashyan O.V., Dyukova G.M., Kolosova K.Yu. Irritable Bowel Syndrome and Intestinal Bowel Disease Associated with IBS-Like Symptoms: Comparative Analysis of Somatoform Symptoms and Patient Psychological and Emotional Characteristics. Academic and Practical Peer-Reviewed Medical Journal Doctor.Ru Gastroenterology. 2015; 12(113): 73–77.
      41. Mnatsakanyan M.G., Dyukova G.M., Pogromov A.P., Tashchyan O.V. Emotional and personality features of patients with irritable bowel syndrome and bowel inflammatory diseases. Klinicheskaya Meditsina. Vol. 94, no. 10, pp. 764–770.
      42. Mitchell A, Guyatt G, Singer J, Irvine EJ, Goodacre R, Tompkins C, Williams N, Wagner F. Quality of life in patients with inflammatory bowel disease. J Clin Gastroenterol. 1988;10:306–310.
      43. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, Kinnear D, Saibil F, McDonald JW. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group. Gastroenterology. 1994;106:287–296.
      44. Hjortswang H, Ström M, Almer S. Health-related quality of life in Swedish patients with ulcerative colitis. Am J Gastroenterol. 1998;93:2203–2211.
      45. Tashchyan O.V. Komorbidnyye simptomy i emotsional'nolichnostnyye osobennosti u bol'nykh sindromom razdrazhennogo kishechnika (SRK) i vospalitel'nymi zabolevaniyami kishechnika (VZK) v stadii remissii s SRK-podobnymi simptomami Diss. Kand. Med. Nauk [Comorbid symptoms and emotional personality traits in patients with irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) in remission with IBS-like symptoms. Candidate of Medical Sciences Diss.] Moscow. 2017.
      46. Belous S.S., I.L. Khalif, O.V. Golovenko, Korneva T.K. The effectiveness of antibacterial therapy in complex treatment of ulcerative colitis with the manifestations of irritable bowel syndrome. Farmateka. 2015; 2(295): 66–71.

    Full text is published :
    Tashchyan O.V., Pogromov A.P., Mnatsakanyan M.G., Morozova Yu.N. Inflammatory bowel diseases in remission with ibs-like symptoms. Experimental and Clinical Gastroenterology. 2018;157(9): 128–133. DOI: 10.31146/1682-8658-ecg-157-9-128-133.
    Read & Download full text

    1. Sechenov First Moscow State Medical University (Moscow, Russia)
    2. Center of Pharmaceutical Analytics LLC (Moscow, Russia)
    3. North-Western State Medical University named after I.I. Mechnikov of the Ministry of Health of the Russian Federation (Saint-Petersburg, Russia)

    Keywords:reference drug of mebeverine hydrochloride, generic drugs of mebeverine hydrochloride, equivalence in vitro, mebeverine, Duspataline®, Niaspam Sparex®.

    Abstract: Purpose of the study: Investigation and comperasion of dissolution kinetics of three mebeverine hydrochloride drugs: Duspatalin® 200 mg prolonged-release capsules, Niaspam 200 mg prolonged-release capsules and Sparex® 200 mg prolonged-release capsules. Materials and methods: For each of mebeverine trade names under test, a total of 6 prolonged-release capsules 200 mg were used in the experiment. Duspatalin® 200 mg, served as a reference product. The study was performed using three dissolution media (рН 1.2; 4.5; 6.8), which modeled GI tract parts where disintegration, release, and absorption of API take place. Sampling points (1, 2, 4, 6, 8, 10, and 12 hours) were selected in such a manner so the dissolution profile of the studied dosage forms would be fully described, including the complete release (the plateau). Results: The dissolution kinetics of generic drugs (Niaspam 200 mg and Sparex® 200 mg prolonged-release capsules) and reference product were found to be equivalent in vitro in media with pH 1.2 and 6.8. At the same time, the dissolution of these drugs was not equivalent at media with pH 4.5, which is characteristic for the stomach antrum. The results of the comparative study show that at pH 4.5 93.66% of the API was released from Niaspam capsules and 98.72% – from Sparex® capsules. The percentage of released API from Duspatalin® capsules was 83.08%. Conclusion: In vitro laboratory studies of mebeverine hydrochloride release rate from three drugs (Duspatalin® 200 mg prolonged-release capsules, Niaspam 200 mg prolonged-release capsules and Sparex® 200 mg prolonged-release capsules) showed that the dissolution kinetics at pH 4.5 of the generic drugs differs from that of the original drug, which may potentially impact on clinical practice. However, further direct comparative clinical studies are required in order to confirm this hypothesis.

      1. Content.aspx?ItemNumber=1673. Обращение от 06.09.2018.
      2. Crombie I.K., Croft P.R., Linton S.J. et al. Epidemiology of pain: a report of the Task Force on Epidemiology of the International Association for the Study of Pain. 1999. IASP Press, Seattle, USA.
      3. Taylor R.B. Difficult diagnosis (2 volumes) (in Russian). Moscow. 1998. 1232 p.
      4. Ivashkin V.T., Sheptulin A.A. Abdominal pain. (in Russian) MEDpressinform. 2012. 110 p.
      5. Camilleri M. Management of the irritable bowel syndrome. Gastroenterology. 2001. 120: 652–668.
      6. Ford A.C., Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther. 2010. 32(2):144–58.
      7. the results of the study PrindexTM "Monitoring the prescribing physician" carried out by LLC "Ipsos KOMKON" in the fall of 2017
      8. Эбботт Лэбораториз ГмбХ, неопубликованные данные [Abbott Laboratories GmbH, Data on File].
      9. Evans P., Bak.P, Kellow J. Mebeverine alters small bowel motility in irritable bowel syndrome. Aliment. Pharmacol. Ther. 1996.10:773–781.
      10. Klimov A.E. Duspatalin in the treatment of the intestine and bile ducts functional disorders. (in Russian) Russian Medical Journal. 2005.5: 285–292.
      11. Darvish-Damavandi M., Nikfar S., Abdollahi M.A. systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome.World J Gastroenterol. 2010. 16(5):547–53.
      13. sredstv-61-fz Федеральный закон «Об обращении лекарственных средств» от 12.04.2010 N 61-ФЗ (ред. от 28.12.2017).
      14. Kawalec P., Holko P., Gawin M. et al. Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis.Arch Med Sci. 2018.14(5):1125–1136.
      15. Solodkov A.S., Sologub E.B. Human Physiology. General. Sports. Age. (in Russian) SPORT. 2016. 485 p.
      16. Instruction leaflet for medical use of the medicinal product Niaspam 200 mg, prolongedrelease capsules, dated 19.09.17.
      17. Instruction leaflet for medical use of the medicinal product Sparex® 200 mg, prolongedrelease capsules, dated 26.02.18
      18. Instruction leaflet for medical use of the medicinal product Duspatalin® 200 mg, prolonged-release capsules, dated 01.11.17
      19. Stockis A., Guelen P.J., de Vos D. Identification of mebeverine acid as the main circulating metabolite of mebeverine in man.J Pharm Biomed Anal. 2002. 29(1–2):335–40.
      20. Inauen W., Halter F. Clinical efficacy, safety and tolerance of mebeverine prolonged release (200 mg) vs. mebeverine tablets in patients with irritable bowel syndrome. Drug Invest. 1994. 8:234–40
      21. Delvaux M., Ribet A. Etude de l efficacite, de l’innocuite et de la tolerance de DuspatalinR 200 mg gelules chez des patients presentant des troubles fonctionnels du tractus gastro-intestinal (colopathie fonctionnelle). Abstract Gastro 1994.84: 2–3.
      22. Van Outryve M, Mayeur S, Meeus MA et al. A doubleblind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome. J Clin Pharm Ther. 1995. 20: 277–82.
      23. Winsemius A., Meuwsen I.M., Boon C. et al. A pharmacokinetic comparison of the modified release capsule and a plain tablet formulation of mebeverine. IntJClinPract. 2002; 9 (56): 659–662.

    Full text is published :
    Ramenskaya G.V., Shokhin I.E., Simanenkov V.I., Tihonov S.V. Prolonged-release dosage forms of mebeverine hydrochloride: clinical pharmacological and pharmaceutical aspects. Experimental and Clinical Gastroenterology. 2018;157(9): 134–141. DOI: 10.31146/1682-8658-ecg-157-9-134-141.
    Read & Download full text

    1. State-funded Educational Establishment of Higher Professional Education «Volgograd State Medical University of the Ministry of Public Health of the Russian Federation» (400131, Volgograd, Russia)

    Keywords:cholelithiasis, "biliary pain", stones, dyspeptic syndrome

    Abstract: This review focuses on the clinical picture, approaches to the diagnosis and treatment of cholelithiasis.

      1. Ward S,Rogers G. Diagnosis and management of gallstone disease: summary of NICE guidance. BMJ 2014; 349.
      2. Testoni РА. Acute recurrent pancreatitis: Etiopathogenesis, diagnosis and treatment. World J Gastroenterol. 2014 Dec 7; 20(45): 16891–16901.
      3. Ivashkin V.T., Bueverov A.O. Racional'naya farmakoterapiya v gepatologii: rukovodstvo dlya praktikuyushchih vrachej [Rational pharmacotherapy in Hepatology: a guide for practitioners]. Moscow, Litterra, 2009. — 624 p.
      4. Ivashkin V.T., Lapina T.L., red. Gastroenterologiya: nacional'noe rukovodstvo [Gastroenterology: national leadership]-Moscow, GEOTAR-Media, 2008. — 700 p.
      5. Kalinin A.V., Hazanov A.I., red. Gastroenterologiya i gepatologiya: diagnostika i lechenie: rukovodstvo dlya vrachej. [Gastroenterology and Hepatology: diagnosis and treatment]. Moscow, Miklos, 2007. — 600 p.
      6. Ivashkin V.T. Klinicheskie rekomendacii. Gastroenterologiya [Clinical guidelines. Gastroenterology]. Moscow, GEOTAR-Media, 2008. — 182 p.
      7. Ivashkin V.T., Lapina T.L., Ohlobystin A.V., Bueverov A.O. Naibolee rasprostranennye zabolevaniya zheludochno-kishechnogo trakta i pecheni: sprav. dlya praktikuyushchih vrachej [the Most common diseases of the gastrointestinal tract and liver: right. for practicing physicians]. Moscow, Litterra Publ., 2008. — 170 p.
      8. Kalinin A.V., Hazanov A.I. Gastroenterologiya i gepatologiya. Diagnostika i lechenie. Rukovodstvo dlya vrachej. [Gastroenterology and Hepatology. Diagnosis and treatment.] Moscow, Izdatel'stvo MIKLOSh Publ., 2007.
      9. Bolotovskij G.V. Holecistit i drugie bolezni zhelchnogo puzyrya [Cholecystitis and other gallbladder diseases:] omega, 2007.
      10. Kuchanskaya A. V. Zhelchnokamennaya bolezn'. Sovremennyj vzglyad na lechenie i profilaktiku [Modern view on treatment and prevention:] is "All" Publ., 2007.
      11. Lejshner U. Prakticheskoe rukovodstvo po zabolevaniyam zhelchnyh putej. [A practical guide to disorders of the bile ducts.] Moscow, GEOTAR-MED Publ., 2004.
      12. Yakovenko E.P., Grigor'ev P.Ya. Hronicheskie zabolevaniya vnepechenochnyh zhelchevyvodyashchih putej (diagnostika i lechenie). Metodicheskoe posobie dlya vrachej. [Chronic diseases of extrahepatic biliary tract (diagnosis and treatment). Methodical manual for doctors.] Moscow, Medical Practice Publ., 2003.
      13. Milyutin V.A, Tkach N.S. M. Azbuka zhizni pri zhelchnokamennoj bolezni. [The ABC of life in cholelithiasis.] Moscow, 2011.
      14. Ahmedov V. A. Prakticheskaya gastroenterologiya. [Practical gastroenterology.] Moscow, Medical news Agency, 2011. — 416 p.
      15. Badretdinova A.R. Analiz faktorov riska razvitiya holecistolitiaza u bol'nyh pered planovoj holecistektomiej // Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii (prilozhenie № 38): materialy 17-j Rossijskoj gastroenterologicheskoj nedeli. [Analysis of risk factors for cholecystolithiasis in patients before planned cholecystectomy / the Russian journal of gastroenterology, Hepatology, Coloproctology (Appendix № 38): materials of the 17th Russian gastroenterological week.] 10–12 October 2011. Moscow, 2011. P. 107.
      16. Galkin V.A. Zabolevaniya zhelchnogo puzyrya i zhelchevyvodyashchih putej. [Diseases of the gallbladder and biliary tract.] Moscow, Phoenix, 2014. 128 P.
      17. Polunina T.E., Polunina E.V. Hronicheskij holecistit [Chronic cholecystitis.] Lechashchij vrach. — 2010. — № 4. — P. 31–32.
      18. Kayushev P.E., Tereshchenko I.V. Izmenenie roli faktorov riska ZhKB v nastoyashchee vremya // Rossijskij Zhurnal gastroenterologii, gepatologii,kolop roktologii(prilozhenie № 40):materialy 18-j Rossijskoj gastroenterologicheskoj nedeli. M., 8–10 oktyabrya [Causes P. E., Tereshchenko I. V., the Changing role of risk factors of GSD currently // Russian journal of gastroenterology, Hepatology, Coloproctology (Appendix № 40):the materials of the 18th Russian gastroenterology week.] 8–10 October 2012-Moscow, 2012. — P. 109.
      19. Samsonov A.A. Sovremennaya terapiya hronicheskogo holecistita i diskinezii zhelchevyvodyashchih putej // Rossijskij medicinskij zhurnal.[Modern therapy of chronic cholecystitis and biliary dyskinesia // Russian medical journal.] — 2009, — no. 6, — P. 13–17.
      20. Voprosy strategii i taktiki profilaktiki donozologicheskih sostoyanij i zabolevanij vnutrennih organov. V.G.Radchenko i soavt.[Questions of strategy and tactics of prevention of prenosological conditions and diseases of internal organs.] Moscow, 2011.
      21. Radchenko V.G. et al. Zabolevaniya pecheni i zhelchevyvodyashchih putej. [Diseases of the liver and biliary tract.] SPb, Spetslit, 2011. — 526 p.
      22. Anisimova E.V., Kozlova I.V., Volkov S.V. Klinicheskie i ul'trazvukovye osobennosti zabolevanij zhelchnogo puzyrya u pacientov s deficitom massy tela. Klinicheskaya medicina [Clinical and ultrasound features of gallbladder diseases in patients with body weight deficit. Clinical medicine] — 2014, — no.2, — P. 43–47.
      23. Seliverstov P.V. Funkcional'nye rasstrojstva biliarnogo trakta i ih lechenie [Functional disorders of the biliary tract and their treatment]. Vrach. — 2012, — no. 3, — P. 9–14.
      24. Skvorcova T.E. Kompleksnyj podhod k lecheniyu bol'nyh zhelchekamennoj bolezn'yu [an Integrated approach to the treatment of patients with cholelithiasis]. Vrach. — 2011. — No. 4. — P. 2–6.
      25. Maksimov V.A. et al. Sovremennaya terapiya zabolevanij organov pishchevareniya. [Modern therapy of digestive diseases.] Moscow, "Adamant", 2011.
      26. Spravochnik Vidal'. Lekarstvennye preparaty Rossii. [Directory Vidal. Medicines of Russia.] Astrafarmservis, — 2010, P. B-1190.
      27. Cimerman Ya.S. Klinicheskaya gastroenterologiya. [Clinical gastroenterology.] Moscow, "GEOTAR-Media", 2009.
      28. Anisimova E.V., Kozlova I.V., Volkov S.V. Hronicheskij holecistit u pacientov s razlichnym trofologicheskim Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. [Chronic cholecystitis in patients with different trophological status: mechanisms of occurrence and features of the course. Russian journal of gastroenterology, Hepatology, Coloproctology.] 2014. Vol. 24. No. 3. P. 36–41.
      29. Anisimova E.V., Kozlova I.V., Volkov S.V. Taktika vedeniya pacientov s hronicheskim holecistitom na fone ozhireniya // Medicinskaya nauka i obrazovanie Urala. [Tactics of management of patients with chronic cholecystitis against obesity / / Medical science and education of the Urals]. 2013, Vol. 14, No 1 (73), pp. 7–10.
      30. Anisimova E.V., Kozlova I.V., Volkov S.V., Rozumbaeva L.P. Kliniko-morfologicheskie osobennosti pecheni pri zhelchnokamennoj bolezni. [Clinical and morphological features of the liver in cholelithiasis.]. Astrahanskij medicinskij zhurnal — Astrakhan medical journal. 2012, Vol. 7, No. 3, pp. 40–43.
      31. Anisimova E.V., Kozlova I.V., Volkov S.V. Osobennosti pishchevogo povedeniya pri boleznyah zhelchnogo puzyrya [Features of food behavior in diseases of the gallbladder]. Fundamental'nye issledovaniya — Fundamental research 2012, No. 7–2, P. 264–268.

    Full text is published :
    Skvortsov V.V., Khalilova U.A. Diagnostics and treatment of cholelithiasis. Experimental and Clinical Gastroenterology. 2018;157(9): 142–150. DOI: 10.31146/1682-8658-ecg-157-9-142-150.
    Read & Download full text